60 DEGREES PHARMACEUTICALS, INC.
About 60 DEGREES PHARMACEUTICALS, INC.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.0M
- Net income
- -$7.4M
- Total assets
- $5.4M
- Market cap
- $3.8M
Source: SEC EDGAR · updated Jun 8, 2026
- Market cap
- $3.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 12, 2023
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review 60 DEGREES PHARMACEUTICALS, INC..